Why the study?
Does FTY720 prolong graft survival and inhibit graft atherosclerosis in a murine model of cardiac transplantation?
Population
Murine model of cardiac transplantation
Comparison
Oral FTY720 in doses of 0.3, 1, 3, or 10… vs Cyclosporin A 40 mg/kg/day as a comparative…
Design
Preclinical
Follow-up
60 days
Authors
Loading...
Supports FTY720 development in transplant models; leaves open human efficacy and safety.
Does FTY720 prolong graft survival and inhibit graft atherosclerosis in a murine model of cardiac transplantation?
FTY720 significantly prolonged cardiac graft survival and inhibited graft atherosclerosis in a murine model, highlighting its potential as a novel immunosuppressant for cardiac transplantation.
Hwang et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: